Abstract
Protein-based therapeutics has become one of the most rapidly growing and successful drug class in the clinic. However, there are still a number of key challenges that need to be addressed before the full therapeutic potential of protein drugs can be realized. Of note, many biologically active proteins have very short in vivo half-lives, a fact that has greatly hindered their clinical applications. Consequently, several different strategies including polyethylene glycol modification and fusion with Fc or albumin have been developed and implemented to prolong the serum half-life of protein therapeutics. Here we will focus on the recent advances in the development of Fc-based antibody fragments and domains and their potential use as novel half-life-extending fusion partners for protein therapeutics.
Keywords: Antibody fragments, protein therapeutics, FcRn, half-life, IgG1 Fc, IgG1 CH2, IgG1 CH3.
Current Pharmaceutical Biotechnology
Title:New Directions for Half-Life Extension of Protein Therapeutics: The Rise of Antibody Fc Domains and Fragments
Volume: 17 Issue: 15
Author(s): Lili Wang and Tianlei Ying
Affiliation:
Keywords: Antibody fragments, protein therapeutics, FcRn, half-life, IgG1 Fc, IgG1 CH2, IgG1 CH3.
Abstract: Protein-based therapeutics has become one of the most rapidly growing and successful drug class in the clinic. However, there are still a number of key challenges that need to be addressed before the full therapeutic potential of protein drugs can be realized. Of note, many biologically active proteins have very short in vivo half-lives, a fact that has greatly hindered their clinical applications. Consequently, several different strategies including polyethylene glycol modification and fusion with Fc or albumin have been developed and implemented to prolong the serum half-life of protein therapeutics. Here we will focus on the recent advances in the development of Fc-based antibody fragments and domains and their potential use as novel half-life-extending fusion partners for protein therapeutics.
Export Options
About this article
Cite this article as:
Wang Lili and Ying Tianlei, New Directions for Half-Life Extension of Protein Therapeutics: The Rise of Antibody Fc Domains and Fragments, Current Pharmaceutical Biotechnology 2016; 17 (15) . https://dx.doi.org/10.2174/1389201017666160823144032
DOI https://dx.doi.org/10.2174/1389201017666160823144032 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Epigenetics in Ocular Diseases
Current Genomics An Insight into the Current Perspective and Potential Drug Targets for Visceral Leishmaniasis (VL)
Current Drug Targets Role of Reactive Oxygen Species in Tumor Necrosis Factor-alpha Induced Endothelial Dysfunction
Current Hypertension Reviews Targeting the Pleiotrophin/Receptor Protein Tyrosine Phosphatase β /ζ Signaling Pathway to Limit Neurotoxicity Induced by Drug Abuse
Mini-Reviews in Medicinal Chemistry Ghrelin and Other Gastrointestinal Peptides Involved in the Control of Food Intake
Mini-Reviews in Medicinal Chemistry Editorial [Hot Topic:Toward Translational Research on VIP AND PACAP (Executive Editor: A. Arimura)]
Current Pharmaceutical Design Proposing a “Lipemic Index” As a Nutritional and Research Tool
Current Vascular Pharmacology The Pathophysiology of Uric Acid in Relation to Cardiovascular Disease
Current Cardiology Reviews Targeting Kinin Receptors for the Treatment of Neurological Diseases
Current Pharmaceutical Design Obesity: Pathophysiology and Clinical Management
Current Medicinal Chemistry Antitumor Activities of Interleukin-27 on Melanoma
Endocrine, Metabolic & Immune Disorders - Drug Targets Progress in Small Molecule and Biologic Therapeutics Targeting Ghrelin Signaling
Mini-Reviews in Medicinal Chemistry The Renin-Angiotensin System: Emerging Concepts
Current Hypertension Reviews Diabetes Care: Risk Factors, Prediction, Prevention, and Individualized Treatment
Infectious Disorders - Drug Targets Artificial Light Pollution at Night: A Risk for Normal Circadian Rhythm and Physiological Functions in Humans
Current Environmental Engineering Editorial [Hot Topic: New Prospects for Treatment of Autoimmune Diseases (Executive Guest Editor: Alessandra Fierabracci)]
Current Pharmaceutical Design Chemical Senses Affecting Cough and Swallowing
Current Pharmaceutical Design Emblica officinalis (Amla) Ameliorates High-Fat Diet Induced Alteration of Cardiovascular Pathophysiology
Cardiovascular & Hematological Agents in Medicinal Chemistry Phytochemical Constituents, HPLC-PDA-ESI-MS/MS Profile and Bioactivities of Roots and Rhizomes of Prosopis farcta (Banks & Sol.) J. F. Macbr.
The Natural Products Journal Nitric Oxide and Dietary Factors: Part III Minerals, Vitamins and Other Dietary and Lifestyle Factors
Vascular Disease Prevention (Discontinued)